Compare SGC & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGC | GOSS |
|---|---|---|
| Founded | 1920 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.7M | 101.2M |
| IPO Year | 1994 | 2018 |
| Metric | SGC | GOSS |
|---|---|---|
| Price | $9.98 | $0.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $16.00 | $4.19 |
| AVG Volume (30 Days) | 36.6K | ★ 26.2M |
| Earning Date | 03-03-2026 | 03-17-2026 |
| Dividend Yield | ★ 5.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $566,184,000.00 | $48,471,000.00 |
| Revenue This Year | $3.23 | N/A |
| Revenue Next Year | $3.82 | $203.01 |
| P/E Ratio | $22.35 | ★ N/A |
| Revenue Growth | ★ 0.09 | N/A |
| 52 Week Low | $8.30 | $0.33 |
| 52 Week High | $13.78 | $3.87 |
| Indicator | SGC | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 23.42 |
| Support Level | $9.73 | $0.33 |
| Resistance Level | $10.49 | $0.60 |
| Average True Range (ATR) | 0.42 | 0.06 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 23.47 | 0.00 |
Superior Group Of Companies Inc designs apparel products. The company operates through three segments: i) The Branded Products segment, under the brands BAMKO and HPI, produces and sells customized merchandising solutions, promotional products, and branded uniform programs. ii) The Healthcare Apparel segment, under the brands Wink and Fashion Seal Healthcare, manufactures and sells healthcare apparel including scrubs, lab coats, protective apparel, and patient garments. iii) The Contact Centers segment, through The Office Gurus entities, provides outsourced, nearshore, and onshore business process outsourcing (BPO), contact center, and call-center support services to customers in North America. The majority of the company's revenue is derived from the Branded Products segment.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.